Essay --

In straightaway days Atrial Fibrillation (AF) is the most ordinary cardiac dysrhythmia that is often seen in clinical practice. There ar 700,000 strokes in the USA each form and 15% of it ca rehearsed by Atrial Fibrillation. For a long period of sentence warfarin was the only viva anticoagulant available in the US for forbearings with atrial fibrillation to prevent stroke events. Recently a new oral anticoagulants, including apixaban, dabigatran, and rivaroxaban have been developed and became available in the US for the stoke measure and systemic embolism for patients with atrial fibrillation. Now, when all three new anticoagulants be available as an alternative to warfarin for the same indication, they make the wellheadness care providers question which agent is the best and for which patients. New agents have functional advantages over warfarin that has many limitations such as need for monitoring, stiff dose adjustment, food and dose interaction and side effects. The major finale of the wellness care providers is to prescribe the safest and the most effective alternative drug and dose to each individual patient with AF. However, the approval for clinical use by the Food and Drug Administration (FDA) and the European Medicine performance differ for anticoagulants and their dosages, and for the individual indication (Harenberg & Kraemer, 2012). Thus, more research needs to be done regarding the monitoring tools for new anticoagulant agents, and extend the use of these agents to separate patient population.Keywords anticoagulants, apixaban, dabigatran, rivaroxaban, warfarin, atrial fibrillation, stroke.Warfarin or New Anticoagulant for injection Prevention in Patients with Atrial FibrillationAtrial Fibrillation (AF) is one of the most common arrhythmias that ... ...s and may not fully understand the importance of their medication, therefor, Advanced pragmatic Nurse should take every opportunity to reinforce the need of the patients to dumbfo und to anticoagulant therapy and may play an important role in patients adherence by providing constant education about their health condition and the importance of their medication.More research should be done on new oral anticoagulants with different study population and similar patients that are seen in everyday clinical practice as well as attempt to define the best pharmacodynamic monitoring tools. Research should be conducted to delimitate monitoring protocol including timing relative to dosing and frequency as well as therapeutic targets. Using these strategies, future trials could enhance further the capacity and safety of these new agents and could extend their use to new indications.